During the past decade, Neurologische Universitätsklinik Heidelberg conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Neurologische Universitätsklinik Heidelberg" #1 sponsor was "Biosite" with 1 trials, followed by "Dr. Frank Behrens" with 1 trials sponsored, "Ferrer Internacional S.A." with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored and "University Hospital Inselspital, Berne" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Neurologische Universitätsklinik Heidelberg" #1 collaborator was "SocraMetrics GmbH" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Neurologische Universitätsklinik Heidelberg" are "Acute Stroke" (1 trials), "Carotid Artery Stenosis" (1 trials), "Cerebral Infarction" (1 trials), "Ischaemic Stroke" (1 trials) and "Multiple Sclerosis, Relapsing-Remitting" (1 trials). Many other conditions were trialed in "Neurologische Universitätsklinik Heidelberg" in a lesser frequency.

Most popular intervention types in "Neurologische Universitätsklinik Heidelberg" are "Drug" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aspirin" (1 trials), "Citicoline" (1 trials), "Clopidogrel" (1 trials), "Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)" (1 trials) and "Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Neurologische Universitätsklinik Heidelberg" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Neurologische Universitätsklinik Heidelberg". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Neurologische Universitätsklinik Heidelberg, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Neurologische Universitätsklinik Heidelberg, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".